Онкология. Журнал им. П. А. Герцена, 2, 2016



Pdf көрінісі
бет12/13
Дата26.12.2023
өлшемі260,06 Kb.
#144024
1   ...   5   6   7   8   9   10   11   12   13
Байланысты:
Onkologia 2016 02 064

ЛИТЕРАТУРА
1. Available at: http://www.wiley.co.uk/genmed/clinical
2. Wang D, Zhong L, Nahid MA, Gao G. The potential of adeno-
associated viral vectors for gene delivery to muscle tissue. 
Expert 
Opin Drug Deliv
. 2014;11(3):345-364. 
doi:10.1517/17425247.2014.871258.
3. Jazwa A, Florczyk U, Jozkowicz A, Dulak J. Gene therapy 
on demand: site specific regulation of gene therapy. 
Gene

2013;525(2):229-238. 
doi:10.1016/j.gene.2013.03.093.
4. Akyurek LM, Yang ZY, Aoki K, San H, Nabel GJ, Parmacek MS 
et al. SM22alpha promoter targets gene expression to vascular 
ОБЗОРЫ ЛИТЕРАТУРЫ


ОНКОЛОГИЯ. ЖУРНАЛ им. П.А. ГЕРЦЕНА, 2, 2016
71
smooth muscle cells in vitro and in vivo. 
Mol Med
. 2000;6(11):983-
991.
5. Lee SJ, Kim HS, Yu R, Bae KH, Stantz KM, Lee SJ et al. Novel 
prostate-specific promoter derived from PSA and PSMA enhanc-
ers. 
Mol Ther. 
2002;6(3):415-421.
6. Smith MJ, Rousculp MD, Goldsmith KT, Curiel DT, Garver RI. 
Surfactant protein A-directed toxin gene kills lung cancer cells in 
vitro. 
Hum Gene Ther.
1994;5(1):29-35.
7. Strayer MS, Guttentag SH, Ballard PL. Targeting type II and Clara 
cells for adenovirus-mediated gene transfer using the surfactant 
protein B promoter. 
Am J Respir Cell Mol Biol
. 1998;18(1):1-11. 
8. Moehle C, Ackermann N, Langmann T, Aslanidis C, Kel A, Kel-
Margoulis O et al. Aberrant intestinal expression and allelic vari-
ants of mucin genes associated with inflammatory bowel disease. 

Mol Med
. 2006;84(12):1055-1066.
9. Kuriyama S, Yoshikawa М, Ishizaka S, Tsujli T, Ikenaka K, Kaga-
wa T et al. A potential approach for gene therapy targeting hepato-
ma using a liver-specific promoter on a retroviral vector. 
Cell Struct 
Funct
. 1991;16(6):503-510.
10. Van Houdt WJ, Haviv YS, Lu B, Wang M, Rivera AA, Ulasov IV et 
al. The human survivin promoter: a novel transcriptional targeting 
strategy for treatment of glioma. 
J Neurosurg
. 2006;104(4):583-
592. 
11. Gu J, Fang B. Telomerase promoter-driven cancer gene therapy. 
Cancer Biol Ther
. 2003;2(4,Suppl.1):S64-S70.
12. Thomas SM, Grandis JR. The current state of head and neck can-
cer gene therapy. 
Hum Gene Ther. 
2009;20(12):1565-1575. 
doi:10.1089/hum.2009.163.
13. Wang W, Li W, Ma N, Steinhoff G. Non-viral gene delivery meth-
ods. 
Curr Pharm Biotechnol. 
2013;14(1):46-60.
14. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the 
use of viral vectors for gene therapy. 
Nat Rev Genet
. 2003;4(5):346-
358. 
15. Yuan Z, Pastoriza J, Quinn T, Libutti S. Targeting tumor vascu-
lature using adeno-associated virus page vector coding tumor ne-
crosis factor-a. In: Lattime EC, Gerson SL, eds. 
Gene therapy of 
cancer
. 3rd ed. San Diego (CA): Elsevier; 2013:19-33. 
doi:10.1038/cgt.2012.83.
16. Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, 
Berry CC et al. Efficacy of gene therapy for X-linked severe 
combined immunodeficiency. 
N Engl J Med.
2010;363(4):355-364.
doi:10.1056/NEJMoa1000164.
17. Bangari DS, Mittal SK. Current strategies and future directions 
for eluding adenoviral vector immunity. 
Curr Gene Ther

2006;6(2):215-226.
18. Palmer DJ, Ng P. Helper-dependent adenoviral vectors for gene 
therapy. 
Hum Gene Ther. 
2005;16(1):1-16.
19. Wen S, Graf S, Massey PG, Dichek DA. Improved vascular gene 
transfer with a helper-dependent adenoviral vector. 


Достарыңызбен бөлісу:
1   ...   5   6   7   8   9   10   11   12   13




©emirsaba.org 2024
әкімшілігінің қараңыз

    Басты бет